Rhythm Pharma Raises $21 Million
Rhythm Pharmaceuticals, a Boston-based developer of peptide therapeutics for metabolic diseases, has held a $21 million first close on its Series A funding. MPM Capital and New Enterprise Associates co-led the financing, which will be used to developer products licensed from Ipsen (Euronext: IPN).
15 March 2010•2 mins read
